PureTech Health PLC Total Voting Rights (2865R)

TIDMPRTC

RNS Number : 2865R

PureTech Health PLC

01 July 2020

PureTech Health plc

Total Voting Rights and Share Capital - Month End Disclosure

Pursuant to DTR 5.6.1 of the Disclosure Guidance and Transparency Rules:

As at 30 June 2020 the issued share capital of PureTech Health plc comprised 285,512,461 Ordinary Shares of one pence each, which is 36,856 Ordinary Shares more than the issued share capital as of 29 February 2020. There were no shares held in treasury.

The total number of voting rights in PureTech Health plc is therefore 285,512,461.

This information may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 24 products and product candidates, including two that have been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 
 Contact: 
  Investors                  EU media 
 Allison Mead Talbot       Ben Atwell, Rob Winder 
  +1 617 651 3156           +44 (0) 20 3727 1000 
  amt@puretechhealth.com    ben.atwell@FTIconsulting.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRPPUGAQUPUGRQ

(END) Dow Jones Newswires

July 01, 2020 02:00 ET (06:00 GMT)

Puretech Health (LSE:PRTC)
Historical Stock Chart
From Oct 2024 to Nov 2024